Intranasal administration of 256 µg Budesonide once daily effectively relieved overall nasal symptoms as well as sneezing/itching in people with rhinitis.

A randomized controlled trial was carried out to evaluate the efficacy profile of intranasal Budesonide in people with symptoms of self-reported rhinitis triggered/exacerbated by airborne pollution.

The study comprised a total of 206 participants, with 103 participants in each group. Participants were randomly assigned to receive Budesonide 256 µg/day or placebo for ten days during the pollution period.

The average change from baseline in the 24-hour reflective total nasal symptom score (rTNSS) over ten days was the major outcome ascertained. Global Impression of Change (SGIC) was analyzed along with a mean alteration from baseline in severity of nasal symptoms and in non-nasal symptoms of cough and postnasal severity of drip.

The final efficacy findings indicated that the Budesonide group had a larger 10-day mean rTNSS change as compared to the placebo group (-2.20 vs -1.72). Budesonide also enhanced the 10-day mean sneezing/itching change (− 0.75 vs − 0.51). No significant differences in terms of SGIC and all other individual symptoms were found in either group. Budesonide exhibited acceptable safety and tolerability profile. No novel safety concerns were detected

Compared to placebo, intranasal Budesonide once daily was associated with a higher reduction in overall nasal symptoms and sneezing/itching in people with rhinitis triggered or exacerbated by airborne pollution.